The founding team's initial venture was an AI agent for Alzheimer's patients. Despite its personal meaning, they recognized that long clinical trial cycles made it commercially unviable. They pragmatically spun off the core technology to create GetVocal, targeting enterprise pain points.

The company's origin was entirely serendipitous. Co-founder Steffen-Sebastian Bolz was helping a friend raise funds for a project. Once the money was secured, the original team disassembled. Instead of letting the opportunity die, Bolz's team decided to pursue the now-funded idea themselves, demonstrating how agility can turn unexpected failures into new ventures.

K-36's lead drug was acquired from Novartis not because it was a failed asset, but because it became available during a strategic reorganization. This illustrates a key opportunity for biotech startups: licensing promising preclinical assets that no longer fit a large pharmaceutical company's immediate development focus.

10x Genomics' leadership was highly disciplined, intentionally avoiding therapeutics to focus on life science tools. This strategic focus created a clear market gap that employees like Wyatt McDonnell could see. It presented an opportunity to leave, found Infinimmune, and become a customer of 10x to pursue that untapped potential.

Roivant's early success came from identifying and building companies around promising drug assets that were deemed non-strategic by large pharmaceutical firms. This approach capitalized on undervalued IP and focused execution, pre-dating the now-common trend of pharma spin-outs.

One of Eclipse's incubation models involves convincing large corporations like Rivian to spin out promising internal projects into standalone companies. This allows the new venture to attract specialized talent and external capital while operating as a neutral "Switzerland" that can serve the entire industry, not just its former parent.

Terry Rosen saw an opportunity as big pharma culturally shifted from deep R&D towards an asset-management model. He founded Arcus to fill this gap, building a company focused on the small molecule drug discovery expertise that the industry was starting to abandon, creating a counter-cyclical advantage.

FCDI launched multiple clinical-stage companies (Century, Opsis, Kenai) by providing a proven iPSC technology backbone. This "platform and spinout" model allows new ventures to focus on clinical development rather than early platform discovery, increasing their chances of success and attracting partners.

ProPhet was founded through Ion Labs, a venture studio created by AstraZeneca, Merck, Pfizer, and Teva. This model allows established pharmaceutical giants to identify acute internal challenges and recruit external talent to build dedicated startups aimed at solving them.